Local view for "http://purl.org/linkedpolitics/eu/plenary/2012-10-23-Speech-2-233-171"
| Predicate | Value (sorted: default) |
|---|---|
| rdf:type | |
| dcterms:Date | |
| dcterms:Is Part Of | |
| dcterms:Language | |
| lpv:document identification number |
"en.20121023.13.2-233-171"2
|
| lpv:hasSubsequent | |
| lpv:speaker | |
| lpv:spokenAs | |
| lpv:translated text |
"I voted in favour of the report on the mobilisation of the European Globalisation Adjustment Fund (EGF) in favour of Sweden in support of those who lost their jobs in the pharmaceutical company AstraZeneca. The Swedish authorities maintain that the pharmaceutical sector is increasingly hard-hit by globalisation. It is clear that the negative consequences of globalisation further highlight the added value of the European Globalisation Adjustment Fund as an EU social policy tool. The targeted financial support which it provides for retraining and reintegration programmes for workers affected by mass dismissals is particularly important. Furthermore, the support it provides is a practical expression of the Union’s solidarity. Lastly, the case of Sweden is the best demonstration of the fact that this financial instrument does not confine its operation to countries facing economic and budgetary challenges, but may prove equally useful in helping dismissed workers to reintegrate into the labour market even in economically robust countries. This in turn underlines the importance of the Fund and demonstrates the need to retain it during the next multiannual financial framework 2014-2020."@en1
|
Named graphs describing this resource:
The resource appears as object in 2 triples